Skip to content
drillr.ai

EDIT

Editas Medicine, Inc.

NASDAQ · USHealthcareBiotechnology
$2.88-3.36%

Price as of Jul 20, 2026

EDIT news

Editas Medicine, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

    CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026. Updated Conference Details: * 2026 Jefferies Global Healthcare Conference Format: Presentation Date: June 4, 2026 Time: 2:00 p.m. ET New York, NY To access the live webcast

    Globe Newswire ·

  2. Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

    CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are bei

    Globe Newswire ·

  3. Editas Medicine Announces Proposed Public Offering

    CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be so

    Globe Newswire ·

  4. Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

    Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026 CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company foc

    Globe Newswire ·

  5. Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

    CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued advancement of Editas’ lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the broader potential of the Company’s differentiated upregulation strategy. The data is being presented this week at the 20

    Globe Newswire ·

  6. Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

    CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference,

    Globe Newswire ·